Eli Lilly's Olumiant receives expanded alopecia indication for children 12 and up

RegulatoryapprovedOlumiantPositive

AI Analysis

Summary

Eli Lilly's Olumiant (baricitinib) has received an expanded indication approval for alopecia in children aged 12 and older, extending the drug's use to a younger patient population.

Outcome Details

Expanded indication for alopecia in children aged 12 and older

Importance:6/10

Sentiment:

0.70

FDA approvallabel expansiondermatologypediatric indication

Related Companies

$LLY

Read the original article

Published by Seeking Alpha Healthcare on September 25, 2026 9:56 PM

Read Original